Kreos Capital
VC Fund
London, United Kingdom
Kreos Capital is a VC fund in London focused on Biotechnology and Software. Kreos Capital is Europe's largest and leading provider of growth debt to high-growth companies with revenues up to €150 million. Since 1998, as the pioneer growth debt provider across the UK, Western Europe, Scandinavia and Israel: Kreos has completed nearly 450 transactions and committed €1.8 billion in 14 different countries. Kreos has aproven track record of adding value to portfolio companies and helping them to grow with additional capital and flexibility throughout their business cycle whilst working closely with both the portfolio company management team and their equity sponsors.The Kreos global team has extensive debt financing, management and equity investing experience, covering the pan-European market from its locations in London, Tel Aviv and Stockholm.Kreos is a value added partner, able to offer additional capital and more flexibility with lower equity dilution. Kreos's international team has extensive entrepreneurial, debt financing and equity investing experience, covering all local European markets from its locations in London, Tel Aviv and Stockholm.
- Total investments:
- 133
- Last investment:
- Lead investor:
- 41%
- Fund size:
- $1.3B
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Kreos Capital invests in
Stages Kreos Capital invests in
Countries Kreos Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Series B
- $11M–$60M
- Post-IPO Debt
- $5.4M–$30M
- Debt Financing
- $5.5M–$53M
Investment Focus
Industry
- Biotechnology 25 (19%)
- Software 24 (18%)
- Health Care 24 (18%)
- Medical Device 16 (12%)
- Financial Services 16 (12%)
Stage
- Debt Financing 33 (25%)
- Post-IPO Debt 19 (14%)
- Series B 17 (13%)
- Series C 13 (10%)
- Series A 12 (9%)
Country
- Germany 19 (14%)
- United Kingdom 18 (14%)
- United States 16 (12%)
- France 13 (10%)
- Israel 11 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Aris Constantinides
General Partner
|
General Partner | Total investments: 2 | Find email | |
Jonne de Leeuw
Venture Partner
|
Venture Partner | Total investments: 9 | Find email | |
Marten Vading
General Partner
|
General Partner | Total investments: 1 | Find email | |
Maurizio PetitBon
General Partner
|
General Partner | Total investments: 7 | Find email | |
Melissa Donohoe
Associate
|
Associate | Total investments: 1 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| McMakler is the leading hybrid real estate agent in Germany. The company combines state-of-the-art marketing technology and central processes at its headquarters in Berlin with a local team of almost 400 permanent real estate agents across Germany in all major regions. With a supported brand awareness of 33%, McMakler is today the best-known realestate agent in Germany and is characterised by its far above-average service quality. | Venture - Series Unknown / Jun 23, 2025 | ||
| Botanix Pharmaceuticals is a pharmaceutical company that focuses on the treatment of skin diseases. Its mission is to improve the lives of patients battling acne, psoriasis, and atopic dermatitis by providing new treatment options for conditions that are currently inadequately addressed or are treated with therapeutics that are burdened with sideeffect profiles. The company is harnessing the untapped potential of a synthetic active pharmaceutical ingredient known as cannabidiol, which is currently being studied for the treatment of epilepsy, pain, arthritis, and schizophrenia, amongst other indications. Botanix is preparing for human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (PermetrexTM) for direct skin delivery of the therapy. | $20.2M / Post-IPO Debt / Jun 10, 2025 | ||
| BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel. The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies. | $20M / Post-IPO Debt / Apr 10, 2024 | ||
| Abivax is a clinical-stage biotechnology company, that mobilizes the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Their aim is to use Abivax's drug development platforms to provide novel and effective treatments to patients with large unmet needs in these therapeutic areas. | $164.6M / Post-IPO Debt / Aug 21, 2023 | ||
| Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies. | $32M / Jul 24, 2023 | ||
| Qover is an insurtech that enables companies and insurance providers to offer seamless, tech-driven insurance experiences.Qover’s modular embedded insurance orchestration platform provides meaningful insurance experiences to millions of users across 32 European countries, and works with longstanding partners like Revolut, Mastercard, NIO, Canyonand many others. | $30M / Series C / Jul 06, 2023 | ||
| Sdui is the solution for mobile communication in schools. With amazingly easy features for messaging, timetables and a wide range of third party integrations, the app digitizes processes and reduces administrative effort. Within two years, Sdui has reached hundreds of institutions and grown a serious reputation in the educational market. | $19.8M / Series A / Feb 01, 2023 | ||
| FINBOURNE Technology was founded in December 2016 with a mission to reduce the cost of investing and increase transparency for everyone. The company has grown from seven founders to over 130 people in less than five years. Our SaaS-native solutions offer greater agility and control, designed to deliver a new standard for data management, with afaster time to market. Built as a bitemporal engine and using open APIs, LUSID® ingests and translates data across organisations’ existing operational stack and wider ecosystem. The data platform supports IBOR, ABOR, tax-lot accounting, valuation and risk workflows. While, Luminesce®, a data virtualisation engine, solves the need to find and securely gather an extended world of data in real-time, enabling deeper insights and analytics. Together, they cover a depth of critical data management processes, for start-up managers, through to global investment institutions. | $37M / Debt Financing / Jan 30, 2023 | ||
| Ukio provides an alternative to the traditional housing market by offering a network of design-forward, turnkey apartments for monthly stays. | $17.4M / Series A / Nov 21, 2022 | ||
| Beekeeper is a mobile-first communication platform that reaches every shift, location, and language through real-time messaging and targeted streams. Managers keep frontline teams productive and turnover low by automating workflows while leveraging an analytics dashboard to measure engagement. Beekeeper integrates with operational systems, makingthem accessible in one central portal. | $50M / Series C / Nov 09, 2022 | ||
| See all 133 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Kreos Capital invest in?
Kreos Capital invests primarily in Biotechnology, Software and Health Care startups, most often at Debt Financing and Post-IPO Debt stage. Most of the 133 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Kreos Capital's check size?
Kreos Capital typically joins rounds of $11M–$60M at Series B, $5.4M–$30M at Post-IPO Debt and $5.5M–$53M at Debt Financing. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Kreos Capital participates in.
How do I contact Kreos Capital?
Public channels for Kreos Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Kreos Capital?
The team at Kreos Capital includes Aris Constantinides (General Partner), Jonne de Leeuw (Venture Partner) and Marten Vading (General Partner), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
